DS
CTKB icon

David Shaw’s Cytek Biosciences CTKB Stock Holding History

David Shaw’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.96M Buy
669,182
+409,057
+157% +$1.75M ﹤0.01% 2857
2026
Q1 		$1.14M Sell
260,125
-3,001
-1% -$14.2K ﹤0.01% 3356
2025
Q4 		$1.33M Buy
263,126
+142,104
+117% +$660K ﹤0.01% 3355
2025
Q3 		$420K Buy
+121,022
New +$454K ﹤0.01% 3947
2023
Q2 		– Sell
-133,249
Closed -$1.22M – 4287
2023
Q1 		$1.22M Sell
133,249
-56,430
-30% -$607K ﹤0.01% 3015
2022
Q4 		$1.94M Buy
189,679
+102,166
+117% +$1.37M ﹤0.01% 2972
2022
Q3 		$1.29M Sell
87,513
-123,289
-58% -$1.6M ﹤0.01% 3391
2022
Q2 		$2.26M Sell
210,802
-523,254
-71% -$5.21M ﹤0.01% 2958
2022
Q1 		$7.91M Buy
734,056
+718,217
+4,534% +$9.7M 0.01% 1824
2021
Q4 		$258K Buy
+15,839
New +$332K ﹤0.01% 4754

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

David Shaw's CTKB Position: Q2 2026 in Review

David Shaw increased its Cytek Biosciences (CTKB) stake by 157% in Q2 2026, buying an estimated $1.75M and bringing the position to 669,182 shares worth $2.96M. The position accounts for ﹤0.01% of the portfolio, ranked #2857.

David Shaw first reported a position in CTKB in Q4 2021 and has held it in 10 quarters since. The position peaked at $7.91M in Q1 2022. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • David Shaw held 669,182 shares of Cytek Biosciences worth $2.96M as of Q2 2026.
  • David Shaw bought 409,057 Cytek Biosciences shares in Q2 2026, an estimated $1.75M.
  • Cytek Biosciences made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2857 holding.
  • David Shaw first reported a position in Cytek Biosciences in Q4 2021 and has held it in 10 quarters since.
  • David Shaw's Cytek Biosciences position peaked at $7.91M in Q1 2022.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.